Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Current Price
$0.24
+16.93%Jupiter Neurosciences Inc (JUNS) Insider Trades
JUNS Insider Trading Activity
Track insider trading transactions for Jupiter Neurosciences Inc (JUNS). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $0.24. Market cap: $7.06M. This page displays the most recent insider transactions for JUNS, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Jupiter Neurosciences Inc's investment outlook.